Pfizer (NYSE:PFE) Shares Down 0.1%

Pfizer Inc. (NYSE:PFE - Get Free Report)'s stock price dropped 0.1% during trading on Tuesday . The company traded as low as $28.36 and last traded at $28.42. Approximately 5,782,936 shares traded hands during trading, a decline of 87% from the average daily volume of 42,934,781 shares. The stock had previously closed at $28.44.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on PFE. BMO Capital Markets reaffirmed an "outperform" rating and issued a $36.00 price objective (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a "buy" rating and a $36.00 price objective for the company. Morgan Stanley increased their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an "equal weight" rating in a report on Thursday, May 2nd. Argus cut Pfizer from a "buy" rating to a "hold" rating in a research note on Friday, March 22nd. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Ten research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Pfizer has an average rating of "Hold" and a consensus price target of $35.86.

Pfizer Trading Down 0.3 %

The firm has a market cap of $160.65 billion, a PE ratio of -472.92, a PEG ratio of 1.18 and a beta of 0.63. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The business has a 50-day moving average price of $27.05 and a two-hundred day moving average price of $28.04.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter in the prior year, the firm earned $1.23 earnings per share. The company's revenue for the quarter was down 19.5% compared to the same quarter last year. Analysts forecast that Pfizer Inc. will post 2.39 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a $0.42 dividend. The ex-dividend date is Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 5.93%. Pfizer's dividend payout ratio is currently -2,799.53%.

Institutional Trading of Pfizer

A number of hedge funds have recently bought and sold shares of PFE. Sheaff Brock Investment Advisors LLC boosted its position in shares of Pfizer by 1.5% in the first quarter. Sheaff Brock Investment Advisors LLC now owns 77,938 shares of the biopharmaceutical company's stock worth $2,163,000 after acquiring an additional 1,188 shares during the last quarter. Heron Bay Capital Management increased its holdings in shares of Pfizer by 513.2% during the 1st quarter. Heron Bay Capital Management now owns 135,857 shares of the biopharmaceutical company's stock worth $3,770,000 after buying an additional 113,700 shares during the last quarter. Advisors Asset Management Inc. raised its position in shares of Pfizer by 13.6% in the 1st quarter. Advisors Asset Management Inc. now owns 655,937 shares of the biopharmaceutical company's stock worth $18,202,000 after buying an additional 78,352 shares during the period. Axxcess Wealth Management LLC grew its position in Pfizer by 4.8% during the first quarter. Axxcess Wealth Management LLC now owns 228,120 shares of the biopharmaceutical company's stock valued at $6,330,000 after acquiring an additional 10,384 shares during the period. Finally, EP Wealth Advisors LLC increased its stake in Pfizer by 0.9% during the first quarter. EP Wealth Advisors LLC now owns 336,062 shares of the biopharmaceutical company's stock worth $9,326,000 after acquiring an additional 2,864 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.